Newsmeme!
Discover News you didn't know existed
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced results from its Phase 2/3 clinical trial, EmbraceAC, comparing its novel anticoagulant agent tecarfarin (previously ATI-5923) with the leading oral anticoagulant warfarin.
By Veronica Gonzalez Veronica.Gonzalez@StarNewsOnline.com When Dr. Howard Marks learned that a 24-year-old woman’s heart was close to bursting because of an aneurysm, he thought he could save her life. After all, Marks, who works at Coastal Thoracic Surgical Associates in Wilmington, has been in private practice here since 1988 and has performed more than 3,000 heart operations here.
FREMONT, Calif.----ARYx Therapeutics, Inc. , a biopharmaceutical company, today announced results from its Phase 2/3 clinical trial, EmbraceAC, comparing its novel anticoagulant agent tecarfarin with the leading oral anticoagulant warfarin.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |